vs
和黄医药（HCM）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
和黄医药的季度营收约是ROGERS CORP的1.4倍（$270.8M vs $200.5M），ROGERS CORP净利率更高（2.2% vs 0.7%，领先1.5%），ROGERS CORP同比增速更快（5.2% vs -16.5%），和黄医药自由现金流更多（$3.4M vs $1.1M）
和黄医药是一家国际化生物制药企业，专注于肿瘤、免疫类疾病的靶向疗法与免疫疗法的研发、生产及商业化，核心市场覆盖中国及全球多个国家地区，已有多款肿瘤治疗药物上市，后期临床管线储备丰富。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
HCM vs ROG — 直观对比
营收规模更大
HCM
是对方的1.4倍
$200.5M
营收增速更快
ROG
高出21.8%
-16.5%
净利率更高
ROG
高出1.5%
0.7%
自由现金流更多
HCM
多$2.3M
$1.1M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $270.8M | $200.5M |
| 净利润 | $2.0M | $4.5M |
| 毛利率 | 37.7% | 32.2% |
| 营业利润率 | -13.2% | — |
| 净利率 | 0.7% | 2.2% |
| 营收同比 | -16.5% | 5.2% |
| 净利润同比 | -83.6% | 421.4% |
| 每股收益（稀释后） | $0.00 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCMROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $270.8M | $201.5M | ||
| Q3 25 | — | $216.0M | ||
| Q2 25 | $277.7M | $202.8M | ||
| Q1 25 | $324.5M | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | — | $210.3M | ||
| Q2 24 | $305.7M | $214.2M |
净利润HCMROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $2.0M | $4.6M | ||
| Q3 25 | — | $8.6M | ||
| Q2 25 | $455.0M | $-73.6M | ||
| Q1 25 | $11.9M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | $25.8M | $8.1M |
毛利率HCMROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 37.7% | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | 0.1% | 31.6% | ||
| Q1 25 | 48.0% | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | 41.1% | 34.1% |
营业利润率HCMROG
| Q1 26 | — | — | ||
| Q4 25 | -13.2% | 3.5% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | -1.3% | -33.3% | ||
| Q1 25 | -5.0% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | -9.0% | 5.3% |
净利率HCMROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 0.7% | 2.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | 163.8% | -36.3% | ||
| Q1 25 | 3.7% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | 8.4% | 3.8% |
每股收益（稀释后）HCMROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.00 | $0.20 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | $0.52 | $-4.00 | ||
| Q1 25 | $0.01 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | $0.03 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $195.8M |
| 总债务越低越好 | $93.2M | — |
| 股东权益账面价值 | $1.2B | $1.2B |
| 总资产 | $1.8B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
现金及短期投资HCMROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $1.4B | $197.0M | ||
| Q3 25 | — | $167.8M | ||
| Q2 25 | $1.4B | $157.2M | ||
| Q1 25 | $836.1M | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | $802.5M | $119.9M |
总债务HCMROG
| Q1 26 | — | — | ||
| Q4 25 | $93.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $93.4M | — | ||
| Q1 25 | $82.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $82.1M | — |
股东权益HCMROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $759.9M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | $740.1M | $1.3B |
总资产HCMROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.8B | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $1.3B | $1.5B |
负债/权益比HCMROG
| Q1 26 | — | — | ||
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.11× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.2M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $3.4M | $1.1M |
| 自由现金流率自由现金流/营收 | 1.2% | 0.5% |
| 资本支出强度资本支出/营收 | 1.8% | 2.3% |
| 现金转化率经营现金流/净利润 | 4.21× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $-96.2M | $70.1M |
8季度趋势，按日历期对齐
经营现金流HCMROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $8.2M | $46.9M | ||
| Q3 25 | — | $28.9M | ||
| Q2 25 | $-72.9M | $13.7M | ||
| Q1 25 | $40.3M | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | $-39.8M | $22.9M |
自由现金流HCMROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $3.4M | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | $-82.2M | $5.6M | ||
| Q1 25 | $32.5M | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | $-49.9M | $8.8M |
自由现金流率HCMROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.2% | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | -29.6% | 2.8% | ||
| Q1 25 | 10.0% | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | -16.3% | 4.1% |
资本支出强度HCMROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.8% | 2.3% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | 3.3% | 4.0% | ||
| Q1 25 | 2.4% | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | 3.3% | 6.6% |
现金转化率HCMROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 4.21× | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | 3.38× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | -1.54× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
